FACTOR IX ANALOGUES HAVING PROLONGED IN VIVO HALF LIFE
摘要
The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue.
申请公布号
WO2007135182(A3)
申请公布日期
2008.04.03
申请号
WO2007EP55031
申请日期
2007.05.24
申请人
NOVO NORDISK HEALTH CARE AG;OESTERGAARD, HENRIK;OLSEN, OLE, HVILSTED;STENNICKE, HENNING, RALF;STEENSTRUP, THOMAS, DOCK
发明人
OESTERGAARD, HENRIK;OLSEN, OLE, HVILSTED;STENNICKE, HENNING, RALF;STEENSTRUP, THOMAS, DOCK